title: Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis.
authors.affiliation: EA 4266, Université de Bourgogne Franche-Comté, Besançon; &, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, F-25030, Besançon, France.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
authors.affiliation: EA 4267, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon; &, Department of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, F-25030, Besançon, France.
authors.forename: Clément
authors.initials: C
authors.lastname: Prati
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
chemical_list: D018501:Antirheumatic Agents; D047428:Protein Kinase Inhibitors
keywords: apremilast; kinase inhibitors; nilotinib; psoriatic arthritis; spondyloarthritis; tofacitinib; treatment; tsDMARD